Table 4.
Radiographic responses and MRI changes after treatment with bevacizumab
| Studies | No of patients | Radiographic responses | T1 Gd enhancement volume reduction (mean) | T2 FLAIR volume reduction (mean) |
|---|---|---|---|---|
| Wang, et al. (2012) [50] | 5 | 4 (80%) | 63.5% | 49% |
| Furuse, et al. (2013) [52] | 3 | 100% | 75.1% | |
| Boothe, et al. (2013) [51] | 11 | 100% | 67.1% | 54.1% |
| Alessandretti, et al. (2013) [48] | 2 | 100% | ||
| Yonezawa, et al. (2014) [53] | 2 | 100% | 49.5% | 76.9% |
| Xiang-Pan, et al. (2015) [49] | 1 | 100% | ||
| Sadraei, et al. (2015) [54] | 17 | 16 (95.8%) | 52% | 53.7% |
| Zhuang, et al. (2015) [55] | 14 | 13 (92.9%) | 36% | 59% |
| Ma, Y., et al. (2017) [57] | 2 | 100% | ||
| Glitza, I. et al. (2017) [58] | 7 | 5 (71%) | ||
| Zhuang, et al. (2019) [33] | 21 | 20 (95.2%) | 35% | 74% |
| Tanigawa, et al. (2019) [56] | 4 | 100% | ||
| This study | 89 | 83 (93%) | Mean: 47.03% (+/− 24.4) | Mean: 61.78% (+/− 23.2) |